I'm sure their number one concern is for patients :)
In all seriousness, the ObamaCare rules on waiving the pharmaceutical fee for “orphan” drugs could have been written more clearly. I’m pretty sure it was Congress’ intention to waive the fee for any drugs that address a very small patient pool; however, the IRS is allowing the waiver only for drugs with an FDA orphan designation.
Market Data 
Markets 
AI
